Bayesian network meta-analysis of 27 placebo-controlled trials (2,318 adults) in generalised myasthenia gravis: FcRn inhibitors, C5 complement inhibitors and CD19+ B-cell depletion showed comparable QMG and MG-ADL gains; FcRn inhibitors had more treatment-related adverse events.
Meta-analysisn = 2,318
McLaren et al. Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis